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Final urinary acidification is achieved by electrogenic
vacuolar Hþ -ATPases expressed in acid-secretory
intercalated cells (ICs) in the connecting tubule (CNT) and the
cortical (CCD) and initial medullary collecting duct (MCD),
respectively. Electrogenic Naþ reabsorption via epithelial
Naþ channels (ENaCs) in the apical membrane of the
segment-specific CNT and collecting duct cells may promote
Hþ -ATPases-mediated proton secretion by creating a more
lumen-negative voltage. The exact localization where this
supposed functional interaction takes place is unknown. We
used several mouse models performing renal clearance
experiments and assessed the furosemide-induced urinary
acidification. Increasing Naþ delivery to the CNT and CCD by
blocking Naþ reabsorption in the thick ascending limb with
furosemide enhanced urinary acidification and net acid
excretion. This effect of furosemide was abolished with
amiloride or benzamil blocking ENaC action. In mice deficient
for the IC-specific B1 subunit of the vacuolar Hþ -ATPase,
furosemide led to only a small urinary acidification. In
contrast, in mice with a kidney-specific inactivation of the
alpha subunit of ENaC in the CCD and MCD, but not in the
CNT, furosemide alone and in combination with
hydrochlorothiazide induced normal urinary acidification.
These results suggest that the B1 vacuolar Hþ -ATPase
subunit is necessary for the furosemide-induced acute
urinary acidification. Loss of ENaC channels in the CCD and
MCD does not affect this acidification. Thus, functional
expression of ENaC channels in the CNT is sufficient for
furosemide-stimulated urinary acidification and identifies the
CNT as a major segment in electrogenic urinary acidification.
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The kidneys play a central role in maintaining acid–base
homeostasis by reabsorbing bicarbonate and excreting acid
equivalents generated by metabolism. Final urinary acidifica-
tion takes place in the connecting tubule (CNT) and along
the different segments of the collecting duct (CD) namely the
cortical (CCD), outer medullary, and initial inner medullary
collecting duct (MCD). These parts of the nephron are
composed of segment-specific cells reabsorbing Naþ and
secreting Kþ and of intercalated cells (ICs) involved in
acid–base transport. Many studies have described functionally
and morphologically at least two types of ICs: type A and
type B.1–3 Type A ICs secrete protons via an apically expressed
vacuolar Hþ -ATPase.4 This proton secretion is functionally
coupled to the basolateral anion exchanger AE1 releasing
bicarbonate into blood. Type B ICs reverse this process,
thereby secreting bicarbonate into urine and absorbing
protons.1,5 The role of a third subtype, non-A/non-B ICs, is
not fully clarified yet.
Proton secretion through vacuolar Hþ -ATPases in the
CNT and CCD is electrogenic and is thought to be indirectly
coupled to Naþ reabsorption.4,6 Naþ reabsorption through
the amiloride-sensitive epithelial Naþ channel (ENaC)
expressed in neighboring segment-specific cells creates a
more lumen-negative potential which has been hypothetized
to enhance Hþ secretion by Hþ -ATPases.7–10 In the MCD,
ENaC expression is much lower than in the CNT and CCD,11
the lumen potential is more positive and Hþ secretion is
independent from Naþ absorption.12
The ENaC consists of three subunits termed a, b, g.13,14
Loss-of-function mutations in either the human a, b, or g
subunits of ENaC cause pseudohypoaldosteronism type 1
characterized by severe neonatal salt wasting, hyperkalemia,
and metabolic acidosis.15 The a subunit plays an essential role
in the trafficking of the channel to the cell surface as well as
forming part of the pore.13 Apart from the kidney, ENaC is
also expressed in distal colon and in upper and lower airways
where it also mediates Naþ reabsorption.14 Mice with
complete inactivation of aENaC develop acute postnatal
respiratory distress and die within 40 h of birth from failure
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to clear their lungs from liquid.16 Recently, a novel mouse
model has been generated with specific inactivation of
aENaC in the entire CD but not in CNT,17 providing a tool
for studying sodium balance as well as disturbances of proton
secretion secondary to defective Naþ absorption.
The vacuolar Hþ -ATPase is composed of at least 13
subunits of which several cell- and tissue-specific isoforms
exist.4,18,19 The B subunit forms part of the peripheral
domain V1 and two isoforms of this subunit, B1 and B2, have
been identified. Whereas the B2 isoform (ATP6V1B2) is
almost ubiquitously expressed and appears to serve in most
cells a house-keeping function, the B1 isoform (ATP6V1B1)
has a more limited tissue distribution: specialized cells of the
epididymis,20,21 the vas deferens,21 the ciliary body of the
eye,22 the inner ear,23 and all subtypes of ICs of the
kidney.20,24 Mutations in the gene encoding the B1 subunit
result in distal renal tubular acidosis (dRTA) in man
characterized by the inability of the distal nephron to
appropriately acidify the urine.23 A mouse model deficient
for the Atp6v1b1 gene has recently been generated with
impaired urinary acidification.25 Vacuolar Hþ -ATPase activ-
ity is almost completely absent from the CCD. Interestingly,
enhanced luminal appearance of the B2 subunit has been
noted in B1-deficient ICs, suggesting that the B2 isoform
could compensate for the loss of B1.25 Nevertheless,
Atp6v1b1-deficient mice develop a more severe metabolic
acidosis with inappropriately alkaline urine when challenged
with an oral acid-load (NH4Cl) characteristic of dRTA.
Different subtypes of dRTA have been proposed and
classified based on clinical tests.26,27 These tests include oral
NH4Cl- or parenteral Na2SO4-loading and application of
furosemide, which all lead to an acute urinary acidification in
healthy subjects but not in patients with specific subtypes of
dRTA. Furosemide inhibits the luminal Naþ /Kþ /2Cl
cotransporter in the thick ascending limb, thereby increasing
the delivered fraction of Naþ to the subsequent nephron
segments and stimulating Naþ reabsorption through ENaC.
Patients lacking an appropriate urinary acidification after
furosemide application have been classified as suffering from
the ‘voltage-defective’ form of dRTA.9
In order to test for and localize the possible functional
interaction between Naþ reabsorption and Hþ secretion in
the different parts of the distal nephron, we performed
clearance studies in mice treated acutely with furosemide,
hydrochlorothiazide, and amiloride, and measured urinary
acidification and net acid excretion (NAE).
RESULTS
Colocalization of vacuolar Hþ -ATPase and ENaC in
neighboring cells in the collecting system
Immunostaining of mouse kidney with antibodies against
calbindin D28k, B1 subunit of the vacuolar Hþ -ATPase, and
the b subunit of the ENaC revealed that the B1 subunit of the
Hþ -ATPase is exclusively expressed in CNTs and CDs which
were identified on account of their characteristic localization
in the cortical labyrinth and the medullary rays, respectively,
and by their strong labelling with antibodies against the beta
subunit of the epithelial sodium channel (ENaC) and the
calcium-binding protein calbindin D28k (Figure 1). Higher
magnification showed that the B1 subunit is only expressed
in a subtype of epithelial cells lining CNT and CD that do not
express bENaC or calbindinD28k. This staining pattern is
consistent with an exclusive localization of the B1 subunit in
ICs28,29 which are intermingled between the ENaC (and
calbindin) positive CNT and CD (principal) cells.
The effect of furosemide and amiloride on urinary
acidification
In a first group of control animals, the effect of acute
furosemide and subsequent amiloride application on urinary
Figure 1 | Localization of vacuolar Hþ -ATPases and the ENaC
along the CNT and CCD in mouse kidney. (a–d) Consecutive mouse
kidney sections (a/b and c/d) were stained against the B1 subunit
of the vacuolar Hþ -ATPase, the b subunit of the ENaC, and the
calbindinD28k protein. Original magnification  400. (e–g) Higher
magnification of a CCD. ICs positive for the B1 subunit are marked
with *, arrows indicate segment-specific cells stained for bENaC and
calbindinD28k. Original magnification  650.
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acidification was tested. As shown in Figure 2a, the initial
urinary pH was similar in all groups before the application of
furosemide. A bolus of furosemide (2 mg/g of body weight
(BW)) after 60 min lowered the urinary pH with being
significantly more acidic after 90 min (furosemide: pH
6.1670.08 versus control: pH 6.4970.07), after 120 min
(furosemide: pH 5.7270.10 versus control: pH 6.3970.08),
and 150 min (furosemide: 5.6370.084 versus control: pH
6.1670.05). The furosemide-induced urinary acidification
was completely abolished by the subsequent administration
of amiloride or benzamil, inhibitors of ENaC activity: pH
6.0970.09 in the furosemideþ amiloride group versus
5.7270.10 in furosemide-alone group after 120 min as well
as after 150 min: pH 6.1970.12 for furosemideþ amiloride
versus pH 5.6370.08 for furosemide alone. The urine
production and excretion remained stable in the control
group during the entire experiment, whereas it increased in
furosemide-treated animals from 1.970.3 ml/g after 60 min
to 5.270.8 ml/g after 90 min. A similar effect was observed in
mice treated subsequently with amiloride, resulting in an
increase in urine output from 3.070.6 ml/g BW after 60 min
to 6.570.7 ml/g BW after 90 min. (Figure 2b). The analysis of
urinary electrolyte excretion revealed that the fractional
excretion (FE in %) of sodium and chloride increased in mice
treated with furosemide plus amiloride (Figure 2d and e)
with a maximum after 120 min (FE of sodium 1.6770.31%
for furosemideþ amiloride versus 0.2570.08% in control
and FE of chloride 2.2970.38% in furosemideþ amiloride
versus 0.7070.24% in control). As summarized in Table 1
and Figure 3, furosemide treatment resulted in a slightly
decreased blood potassium concentration (4.870.3 mmol/l
in furosemide versus 5.770.2 mmol/l in control) and
augmented blood bicarbonate concentration (21.070.7 with
furosemide versus 19.771.0 mmol/l under control).
Thus, treatment of mice with furosemide led to the
expected increase in urinary output with an increase in
fractional sodium and potassium excretion accompanied by a
strong urinary acidification as described previously for rats
and humans.9 The stimulation of urinary acidification was
abolished by the ENaC inhibitors amiloride and benzamil
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Figure 2 | Effect of furosemide and amiloride on urinary pH and electrolyte excretion. (a) Application of furosemide (2 mg/g BW)
(n¼ 17) caused acidification of urinary pH compared to untreated wild-type mice (Atp6v1b1 þ /þ , n¼ 13). The effect of furosemide on
urine pH was reversed in mice treated subsequently with amiloride (5 mg/g BW) (n¼ 14) or benzamil (2 mg/g BW) (n¼ 6). (b) Urine production
and excretion remained stable in the control group during the experiment, whereas it increased in furosemide- and amiloride-treated
animals. (c) The FE (%) of potassium increased in furosemide-treated animals and was reversed by the addition of amiloride. (d, e) The
FE % of sodium and chloride showed an increase of both electrolytes in the furosemide- and amiloride-treated animals. *Po0.05 and
**Po0.001 versus control, #Po0.05 between furosemide treatment and furosemideþbenzamil/furosemideþ amiloride.
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consistent with a role of ENaC in the furosemide-induced
urinary acidification. A similar effect of amiloride and the
structurally unrelated ENaC blocker triamterene on the
furosemide-induced urinary acidification has also been
reported in rats.30
The furosemide-induced urinary acidification is reduced in
mice deficient for the IC-specific vacuolar Hþ -ATPase B1
subunit (ATP6V1B1)
To demonstrate that the furosemide-induced urinary acid-
ification depended on the activity of vacuolar Hþ -ATPases
localized in ICs, we used a mouse model deficient for the
IC-specific B1 subunit (Atp6v1b1 /). Atp6v1b1 /
furosemide-treated mice exhibited a markedly higher basal
urine pH than the Atp6v1b1 þ /þ furosemide-treated mice
(pH 7.1970.16 versus 6.4470.10) and only a mild urinary
acidification upon furosemide administration could be
observed: pH 6.8670.15 versus 5.7270.10 after 120 min
(Figure 4a). The residual urinary acidification observed in the
B1-deficient mice may be owing to a partial compensation by
the B2 isoform which is more luminally localized in ICs of
Atp6v1b1 / mice.25 To assess the effect of the treatments
on NAE, we measured total NH3/NH4
þ and total phosphate
excretion in urine and estimated NAE from these data as the
urine samples were too small to measure titratable acidity.
Both total NH3/NH4
þ and total phosphate excretion
increased in response to furosemide as described previously
in rats.30 Application of furosemide increased NAE from
2.970.3 mmol/l/mg/dl creatinine in control animals to
6.270.6 mmol/l/mg/dl creatinine (Figure 4b). In mice given
amiloride, NAE showed a tendency to be lower (P¼ 0.08). In
contrast, in benzamil-treated mice and in the B1-deficient
mice, NAE was significantly lower (benzamil: 3.770.6 mmol/
l/mg/dl creatinine, B1 KO: 4.470.4 mmol/l/mg/dl creati-
nine).
Atp6v1b1 / furosemide-treated mice also had a
strikingly higher urine output than the Atp6v1b1 þ /þ
furosemide-treated mice after 60 min before the furosemide
administration: 3.270.83 ml/g BW versus 1.970.34 ml/g BW
(Figure 4c). Furosemide administration led to a more
profound diuresis in Atp6v1b1 / mice: 8.971.0 ml/g BW
versus 5.270.7 ml/g BW after 90 min (Figure 4c). In addition,
Atp6v1b1 / mice had a significantly lower basal FE of
potassium than Atp6v1b1 þ /þ mice (1.8970.24 versus
6.0970.60%) (Figure 4d), basal FE of sodium (0.0670.01
versus 0.1370.01%) (Figure 4e), and basal FE of chloride
(0.0470.01 versus 0.1470.01%) (Figure 4f) pointing to a
defect in urine concentration. Furosemide administration
further revealed a significant difference in the FE of pota-
ssium, whereas the FE of sodium and chloride did not differ
between Atp6v1b1 / and Atp6v1b1 þ /þ mice (Figure 4e
and f). As summarized in Table 1 and Figure 5, analysis
of blood electrolytes revealed differences in potassium and
bicarbonate levels.
The CD-specific loss of aENaC expression in Scnn1aloxloxCre
mice does not affect the furosemide-induced urinary
acidification and diuretic response
Scnn1aloxloxCre mice lack the alpha subunit of the ENaC in the
CCD and MCD but not in the connecting segment.17 We
used these mice to test for the furosemide-stimulated urinary
acidification. Basal urine output, urine pH, and electrolyte
content were not significantly different between control mice
(Scnn1aloxlox) and mice with the specific ablation of aENaC
expression (Scnn1aloxloxCre) (compare Tables 1 and 2).
Furosemide administration caused urinary acidification in
both genotypes to a similar extent: Scnn1aloxlox and
Scnn1aloxloxCre mice: pH 6.0070.10 versus 5.8970.09 after
120 min (Figure 6a). Also, estimated NAE at the time point
150 min was similar in both groups of mice (Figure 6b;
Scnn1aloxlox 5.470.9 mmol/l/mg/dl creatinine versus
Scnn1aloxloxCre 4.270.6 mmol/l/mg/dl creatinine, P¼ 0.31).
No difference between Scnn1aloxlox and Scnn1aloxloxCre mice in
urine output could be detected (7.971.9 ml/g BW versus
8.271.1 ml/g BW after 90 min.) (Figure 6c). Furosemide also
failed to unmask a possible difference between Scnn1aloxlox
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Figure 3 | Effect of furosemide and amiloride on blood pH and electrolytes. (a–d) Furosemide treatment resulted in decreased blood
potassium concentration as expected from the increased urinary excretion. Blood bicarbonate levels showed a tendency to be higher which did
not reach statistical significance. **Po0.001 versus control.
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and Scnn1aloxloxCre mice in the FE of sodium: 1.8770.42%
versus 2.1370.54% after 120 min (Figure 6e and Table 2).
However, blood electrolyte analysis revealed a significantly
lower blood bicarbonate concentration (23.570.7 mmol/l in
Scnn1aloxlox versus 21.370.7 mmol/l in Scnn1aloxloxCre (Table 2
and Figure 7b). Thus, after application of furosemide, no
significant difference was found in the diuretic response,
urinary acidification, and electrolyte excretion suggesting
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Figure 4 | Effect of furosemide on urine pH and electrolyte excretion in mice deficient for the B1 vacuolar Hþ -ATPase subunit
(Atp6v1b1 /). (a) Atp6v1b1 / received furosemide (2 mg/g BW) (n¼ 9) and urine pH acidified only mildly. **Po0.001 versus control.
(b) Estimated NAE at the time point 30 min and 150 min. NAE increased after furosemide application and the rise in NAE was significantly
reduced after application of benzamil and in the Atp6v1b1-deficient mice (*Po0.05 significant difference between furosemide-treated
animals and other groups). (c) Furosemide administration led to a more profound diuresis in Atp6v1b1 / in comparison to Atp6v1b1
þ /þ mice. (d–f) The FE of Naþ and Cl was similar in both genotypes; however, the FE % for potassium was lower in B1-deficient mice.
Values of control and furosemide-treated animals from Figure 2 are shown again for comparison. *Po0.05 and **Po0.001 versus
Atp6v1b1 þ /þ treated with furosemide.
Venous blood pH
7.0
7.1
7.2
7.3
7.4
pH
Bicarbonate 
16
18
20
22
24
3.0
4.0
5.0
6.0
Sodium/chloride Potassium
110
120
130
140
150
Na+ Cl−
(m
mo
l/l)
(m
mo
l/l)
(m
mo
l/l)
Atp6v1b1+/+control
Atp6v1b1+/+ furosemide
Atp6v1b1−/−  furosemide
*
**
**
a b
c d
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that preserved expression of aENaC in the CNT is sufficient
to maintain the furosemide-induced urinary acidification.
In order to inhibit a possible compensatory increase in
Naþ absorption in the distal tubule via the thiazide-sensitive
Naþ /Cl cotransporter, furosemide was applied together
with hydrochlorothiazide. Figure 8a shows that the urinary
pH of Scnn1aloxloxCre mice did not differ significantly from the
urine pH of Scnn1aloxlox mice before furosemide and
hydrochlorothiazide (furoþHCT) administration. After
administration of furosemide together with hydrochlorothia-
zide (furoþHCT), Scnn1aloxloxCre mice decreased their urine
pH to the same extent as the Scnn1aloxlox mice: pH 5.7770.12
versus pH 5.6670.10 after 120 min. Urine output, fractional
electrolyte excretion and systemic electrolyte, and blood gas
status were not distinguishable between both mouse lines
(Figures 8 and 9 and Table 2).
DISCUSSION
In the present study, we investigated the functional interaction
between renal Naþ reabsorption through ENaC and Hþ
secretion by vacuolar Hþ -ATPases in the connecting segment
and CCD. Both ENaC and vacuolar Hþ -ATPases containing
the B1 subunit isoform are expressed together in the same
nephron segments, namely CNT and CCD in neighboring
cells. Hþ secretion by vacuolar Hþ -ATPases is electrogenic
and thought to be indirectly coupled to Naþ reabsorption.31
According to this hypothesis, Naþ reabsorption through
ENaC creates a more lumen-negative transtubular voltage
which in turn would enhance Hþ secretion by vacuolar Hþ -
ATPases. Thus, the furosemide-induced increase in Naþ
delivery to the CNT and CCD and the subsequent reabsorp-
tion of this delivered fraction through ENaC may result in
urinary acidification mediated by vacuolar Hþ -ATPases.
Table 1 | Summary of blood pH, gas, and electrolytes of wild-type mice left untreated (control) and wild-type
and Atp6V1b1-deficient mice treated with furosemide and amiloride at the end of the experimental period
Atp6v1b1 +/+
control
Atp6v1b1 +/+
furosemide
Atp6v1b1 +/+
furosemide
amiloride
Atp6v1b1 /
furosemide
pH 7.2270.02 7.2470.02 7.2470.02 7.2570.04
pCO2 (mmHg) 50.673.9 50.872.0 47.772.1 53.877.4
HCO3
 (mmol/l) 19.771.0 21.070.7 19.870.4 21.871.6*
K+ (mmol/l) 5.770.2 4.870.3** 5.570.2 4.370.1**
Na+ (mmol/l) 145.570.8 147.770.9 145.470.5 147.671.4
Cl (mmol/l) 121.871.5 120.970.8 121.170.8 119.672.4
Serum creatinine (mg/dl) 0.1470.02 0.1170.01 0.1370.02 0.1270.01
Weight (g) 27.571.5 29.671.1 25.471.1 24.671.0
CrCl/BW 30 min (ml/min/g) 18.374.2 33.476.1 15.674.9 28.576.0
CrCl/BW 90 min (ml/min/g) 18.774.7 44.678.5* 19.073.4 26.675.6
CrCl/BW 120 min (ml/min/g) 13.873.9 33.274.6** 22.177.0 20.379.2
NH3/NH4
+ (mM)/creatinine (mg/dl), 30 min 1.0470.05 0.9470.08 1.4770.52 1.1870.15
NH3/NH4
+ (mM)/creatinine (mg/dl), 150 min 1.4070.0.18 2.6070.08 2.0470.08 2.5670.26
NAE (mM/creatinine (mg/dl), 30 min 1.2171.11 1.0370.07 1.6370.64 1.2970.20
NAE (mM/creatinine (mg/dl), 150 min 2.9170.28 6.1670.59 5.0270.33 4.4070.44*
BW, body weight; CrCl, creatinine clearance; NAE, net acid excretion.
*Marks significant differences Po0.05, **Po0.001.
Table 2 | Summary of blood pH, gas, and electrolytes of Scnn1aloxlox and Scnn1aloxloxCre mice deficient for the alpha ENaC
subunit treated with furosemide and hydrochlorothiazide
Scnn1aloxlox
furosemide
Scnn1aloxloxCre
furosemide
Scnn1aloxlox
furosemide HCT
Scnn1aloxloxCre
furosemide HCT
pH 7.2870.02 7.2870.03 7.3370.03 7.2570.03
PCO2 (mmHg) 51.472.2 47.373.1 43.974.9 55.472.1*
HCO3
 (mmol/l) 23.570.7 21.370.7* 21.970.9 23.371.3
K+ (mmol/l) 4.470.2 4.470.3 4.570.2 4.970.2
Na+ (mmol/l) 147.870.9 147.870.7 147.670.8 148.070.5
Cl (mmol/l) 119.971.8 120.271.3 114.271.5 114.671.6
Serum creatinine (mg/dl) 0.1570.02 0.1170.01 0.1470.03 0.1370.02
Weight (g) 25.471.9 24.971.2 33.671.7 29.971.9
CrCl/BW 30 min (ml/min/g) 14.473.4 21.773.3 24.1576.3 29.074.4
CrCl/BW 90 min (ml/min/g) 21.573.7 20.872.7 21.673.0 22.474.1
CrCl/BW 120 min (ml/min/g) 10.572.0 13.972.2 12.871.7 13.472.4
NH3/NH4
+ (mM)/creatinine (mg/dl), 30 min 1.2570.30 1.4770.73
NH3/NH4
+ (mM)/creatinine (mg/dl), 150 min 2.2470.36 1.8270.24
NAE (mM/creatinine (mg/dl), 30 min 1.4670.32 1.9370.70
NAE (mM/creatinine (mg/dl), 150 min 5.4170.90 4.2570.60
BW, body weight; CrCl, creatinine clearance; NAE, net acid excretion.
*Marks significant differences Po0.05, **Po0.001.
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Several types of defects in distal renal tubular acidification
have been classified based on provocative tests using infusions
containing sulfate, bicarbonate, or phosphate, oral NH4Cl
loading or furosemide application and the respective response
in urinary pH, net acid, and electrolyte excretion as well as the
ability to sustain a blood–urine PCO2 gradient.
32 At least three
types of dRTA have been distinguished, a ‘secretory type’ with
a defect supposed in the proton-secretory proton pumps, a
5.2
30 60 90 120 150 180 210
30 60 90 120 150 180 210 30 60 90 120 150 210
30 60 90 120 150 210
5.4
5.6
5.8
6.0
6.2
6.4
6.6
6.8
Time (min)
Time (min) Time (min)
Time (min)
30 60 90 120 150 210
Time (min)
pH
Furo
Furo
Furo
Scnn1a loxloxCre
Scnn1a loxlox
Scnn1a loxloxCre
Scnn1a loxlox
Scnn1a loxloxCre
Scnn1a loxlox
0
1
2
3
4
5
6
7
N
AE
(m
mo
l/l)
/cr
ea
 (m
g/d
l)
0.0
1.0
2.0
3.0
4.0
5.0
0.0
1.0
2.0
3.0
FE
 (N
a+
) %
FE
 (K
+
) %
FE
 (C
l− )
 %
Ur
in
e 
vo
lu
m
e/
bo
dy
w
e
ig
ht
 (
l/g
)
0.0
4.0
8.0
12.0
0.0
10.0
20.0
30.0
40.0
Furo
Furo
30 min 150 min
a b
c d
e f
Figure 6 | Effect of furosemide on urine pH and electrolyte excretion in Scnn1aloxlox and Scnn1aloxloxCre mice. (a) The effect of furosemide
on urinary acidification in Scnn1aloxlox (n¼ 10) and Scnn1aloxloxCre (n¼ 12) mice. Furosemide administration did not show any difference in urine
pH between Scnn1aloxlox and Scnn1aloxloxCre mice. (b) No difference in the furosemide-induced increase in the estimated rate of NAE was
observed between Scnn1aloxlox and Scnn1aloxloxCre treated with furosemide. (c) Urine volume/BW in Scnn1aloxlox (n¼ 11) and Scnn1aloxloxCre
(n¼ 10) mice. No difference between Scnn1aloxlox and Scnn1aloxloxCre mice in urine output was reported. (d–f) FE of potassium, sodium, and
chloride in Scnn1aloxlox (n¼ 6) and Scnn1aloxloxCre (n¼ 7) mice. Furosemide-induced increase of FE of potassium, sodium, and chloride did not
differ between Scnn1aloxlox and Scnn1aloxloxCre mice.
Sodium/chloride
110.0
120.0
130.0
140.0
150.0
Na+ Cl−
(m
mo
l/l)
(m
mo
l/l)
(m
mo
l/l)
Bicarbonate
16.0
18.0
20.0
22.0
24.0
Venous blood pH
7.0
7.1
7.2
7.3
7.4
pH
Potassium
3.0
3.5
4.0
4.5
5.0
5.5
6.0
*
Scnn1a loxlloxCre
Scnn1a loxlox
a b
c d
Figure 7 | Effect of furosemide on blood pH and electrolytes in Scnn1aloxlox and Scnn1aloxloxCre mice. Scnn1aloxloxCre mice had a
significantly lower bicarbonate concentration. Other parameters were not different. *Po0.05 versus Scnn1aloxlox.
1712 Kidney International (2006) 70, 1706–1716
o r i g i n a l a r t i c l e J Kovacikova et al.: Furosemide-induced urinary acidification
‘back-leak type’ where Hþ or HCO3
 may leak back, and a
‘voltage-defective type’ where the inability to produce an acid
urine may result from the failure to produce a favorable
lumen-negative potential facilitating proton secretion.9,26,33
Consistent with these functional classifications, application of
amiloride to patients and experimental animals reduces
urinary proton secretion.9,32,34 LiCl has been used as another
tool to induce the voltage-dependent defect; however, several
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studies have indicated that the defects induced by LiCl and
amiloride are different.35 The defect induced by administration
of LiCl can be restored by Na2SO4 infusion
32 and is associated
with altered expression levels of Hþ /Kþ -ATPases and Hþ -
ATPases.36
In our experiments, furosemide induced a strong urinary
acidification. This acidification apparently depends on the
activity of vacuolar Hþ -ATPases containing the B1 isoform
as no or only a mild acidification could be observed in
Atp6v1b1 deficient mice. Thus, vacuolar Hþ -ATPases are the
main mediator of the furosemide-induced urinary acidifica-
tion. The result also suggests that Hþ /Kþ -ATPases, the other
potential acid-secretory pumps, do not play an important
role as an acid-secretory mechanism under these experi-
mental conditions. However, we observed a lower urinary
potassium excretion in the B1-deficient mice. The mechan-
ism is presently unknown. A stimulation of Hþ /Kþ -
ATPases, potentially induced by a higher urinary flow rate,
could contribute to this effect.
The effect of furosemide was blunted by amiloride
inhibiting ENaC-dependent Naþ absorption as evident from
the increased fractional Naþ excretion and decreased
fractional Kþ -excretion. In a separate group of animals,
the consequence of the genetic ablation of ENaC channel
function was tested in Scnn1aloxloxCre mice. These animals lack
the alpha subunit of ENaC which is essential for ENaC
function and results in no detectable ENaC channel function
and loss of luminal localization of beta and gamma subunits
in the CCD and outer medullary CD.17 In the CNT, however,
ENaC function and localization has remained normal.17 In
the control and aENaC-deficient mice, furosemide induced
normal urinary acidification with a similar increase in
fractional Naþ , Cl, and Kþ excretion. In order to rule
out a compensatory increase in Naþ absorption by the
thiazide-sensitive Naþ /Cl cotransporter, we also tested for
the combined effect of furosemide and hydrochlorothiazide
which caused a stronger urinary acidification and diuretic
response to the same extent in both groups of animals. Thus,
the furosemide-induced urinary acidification involves the
activity of an amiloride- and benzamil-sensitive mechanism,
most likely ENaC. In view of the normal capacity of
Scnn1aloxloxCr mice to reabsorb Naþ and to respond to
furosemide and hydrochlorothiazide, it appears that the
residual ENaC function in the CNT may be sufficient for the
furosemide-induced urinary acidification. However, it cannot
be completely ruled out that amiloride acts also on a mech-
anism distinct from ENaC and that this mechanism is still
operative in the Scnn1aloxloxCre mice. Based on mathematical
modelling of transport processes involved in acid secretion
and electrolyte transport along the CD, it has been recently
proposed that the generation of a more lumen-negative
potential by the action of ENaC could hardly account for
changes in vacuolar Hþ -ATPase activity.7 Weinstein7 argued
that the change in transtubular voltage is minor compared to
the ability of the pump to be active even against a larger
voltage gradient, and proposed that amiloride interacts also
with other mechanisms. These calculations were made for the
CCD and may not fully apply for the CNT which was
identified here as the main target of furosemide. However,
our results do not completely rule out that some of the
urinary acidification induced by furosemide took place in the
CCD and that amiloride acted on a mechanism distinct from
ENaC. This mechanism, however, remains to be identified
and local opposing pH gradients must also be taken into
consideration. In addition, Hropot et al.30 reported that the
structurally unrelated triamterene has a similar inhibitory
effect on the furosemide-induced urinary acidification
strongly suggesting that ENaC is the common target.
This identifies the CNT as the major segment mediating
furosemide-induced urinary acidification. Similar conclu-
sions have been reached with respect to the Naþ -absorbing
capacity of the CNT versus CCD.17 Further experiments
establishing a complete genetic ablation of aENaC expression
along the entire CNT and CD will be helpful to prove this
hypothesis.
In summary, the furosemide-induced urinary acidification
requires vacuolar Hþ -ATPases containing the B1 subunit, is
inhibited by amiloride, and is not altered in a mouse model
with preserved ENaC function in the CNT but loss of ENaC
function in the CCD and outer medullary collecting duct.
The results point to a hitherto unrecognized major role of the
CNT in electrogenic Hþ -secretion and the urinary acidifica-
tion induced by furosemide.
MATERIALS AND METHODS
Animals
Experiments were performed on Atp6v1b1 þ /þ and Atp6v1b1 /
mice25) and Scnn1aloxloxCre and Scnn1aloxlox mice.17 They were
maintained on a standard diet and had a free access to drinking
water. All experiments were performed according to Swiss Animal
Welfare laws and approved by the Local Veterinary Authority.
The generation, breeding, and genotyping of Atp6v1b1/,
Scnn1aloxlox, and Scnn1aloxloxCre has been described previously.17,25
Blood and urinary parameters
Mice were anesthetized intraperitoneally (ketamine 1 ml/g BW and
xylazine 1 ml/g BW), placed on a heated table maintained at 371C
and a catheter was placed into the urinary bladder. Urine was
collected every 30 min during the whole period of 3.5 h for the
measurement of urine volume, pH, sodium, chloride, potassium,
and creatinine concentrations. To prevent dehydration, mice were
constantly supplemented with 125 mM NaCl and 25 mM NaHCO3
(pH 7.4) according to their urinary output. At the end of the
experiment, heparinized mixed venous blood was collected for the
measurement of pH, blood gases, sodium, potassium, chloride, and
creatinine concentrations. After an initial recovery phase and
collection of a baseline value at 30 min, at 60 min Atp6v1b1 þ /þ ,
Atp6v1b1 /, Scnn1aloxlox, and Scnn1aloxloxCre mice were
administered furosemide 2 mg/g BW subcutaneously; some of the
Scnn1aloxlox and Scnn1aloxloxCre mice were also given hydrochloro-
thiazide 0.05 mg/g BW together with furosemide. Two subgroups of
Atp6v1b1 þ /þ mice received additionally amiloride 5 mg/g BW
subcutaneously or benzamil 2 mg/g BW subcutaneously after 90 and
120 min of the experiment. All drugs were finally dissolved in
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125 mM NaClþ 25 mM NaHCO3. Control mice received only 125 mM
NaClþ 25 mM NaHCO3.
Urinary pH was immediately measured; urine and blood
electrolytes and other blood parameters (pCO2, pO2) were
determined using a blood gas analyzer (ABL 505, Radiometer,
Copenhagen, Denmark). Urinary creatinine was measured by the
Jaffe method. Serum creatinine was determined by an enzymatic
reaction (F DAOS method, Wako Creatinine F L-Type kit, Wako
Chemicals GmbH, Germany). Total urinary NH3/NH4
þ was
measured using the Berthelot protocol,37 total urinary phosphate
using a commercial kit (Sigma, Buchs, Switzerland). NAE was
estimated from the concentration of total NH3/NH4
þ , total
phosphate as the major titratable acid, and urine pH using the
Henderson–Hasselbalch equation and assuming blood pH 7.4.
Immunohistochemistry
Fixation of mouse kidneys and tissue processing for immuno-
histochemistry was performed as described previously.28 Consecu-
tive cryosections (4–5 mm thick) of the fixed kidneys were placed on
chrom-alum gelatine-coated slides, preincubated with 10% normal
goat serum in phosphate-buffered saline, and afterwards incubated
overnight at 41C with mouse-anti-chicken calbindin D28k anti-
bodies (Swant Bellinzona, Switzerland, dilution 1/20 000 in
phosphate-buffered saline-1% bovine serum albumin) that was
applied together with either rabbit-anti-rat bENaC antisera17
(dilution 1/1000 in phosphate-buffered saline-1% bovine serum
albumin) or rabbit-anti-rabbit B1 subunit of Hþ -ATPase20 (dilu-
tion 1/1000 in phosphate-buffered saline-1% bovine serum
albumin). Binding sites of the primary antibodies were revealed
with fluorescein isothiocynate-coupled goat-anti-mouse immuno-
globulin G and Cy3-coupled goat-anti-rabbit immunoglobulin G
(both from Jackson Immuno Research Laboratories, West Grove,
PA, USA).
Statistical analysis
All data were tested for statistical analysis using paired and unpaired
Student’s t-tests and analysis of variance, and only data with Po0.05
were considered statistically significant. A minimum of 6–8 animals
was used for each measurement and treatment.
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